{"release":"wpf-flagship-weight-management","version":"1.4.0","resultsSha256":"7015f8dd771509f9548e11fe120b65641159173a214b88ed02a6a90183b4538e","license":{"name":"Creative Commons Attribution 4.0 International","identifier":"CC-BY-4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"licenseScope":{"covered":["The stable result identifiers (resultId) and the WPF citation strings","WPF's classification of each study's design (kind)","WPF-written estimand summaries (estimand), the analysis-plan section pointers, and the study-specific limitations (limitations)","The field corrections and their basis notes, and the release changelog","The selection, arrangement and structure of the dataset, and its CSV, BibTeX and JSON renderings","WPF-authored verification records (verification): the locator descriptions, verification notes, automated-check descriptions and outcomes, the not-verified lists and WPF's paraphrased summary of the authors' stated limitations","The release metadata and checksum file"],"excluded":["The cited papers and their abstracts, figures and tables (publishers and authors)","Short quotations of third-party text inside verification records (quotedSourceText: registry outcome-measure titles and similar strings). They are marked as third-party","Third-party slide decks and other reproductions linked only as corroboration","ClinicalTrials.gov records, posted results, protocols and statistical analysis plans (linked, not redistributed)","Regulator documents and product labels","Bibliographic identifiers and reported numerical facts as stated by their sources","WPF branding, logos and names","WPF films, transcripts and website copy","WPF repository code"],"unclearAndExcluded":["Fields that closely restate source reports: population, comparator, endpoint, followUp, result, uncertainty, discontinuation, funder and trial names. Ownership of this wording is unresolved, so it is outside the licensed scope until the Owner decides otherwise."]},"suggestedAttribution":"World Peptide Foundation, \"WPF Flagship Weight Management\", version 1.4.0 (2026-11-14), https://www.worldpeptidefoundation.org/releases/wpf-flagship-weight-management/1.4.0/release.json. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Please indicate whether you made changes.","result":{"resultId":"jama-intern-med-2024-realworld","candidateId":"tirzepatide:6","kind":"observational_cohort","trial":"Rodriguez and colleagues, JAMA Internal Medicine 2024: cohort study, not a randomized trial","agents":"Tirzepatide vs semaglutide (formulations labeled for type 2 diabetes, on or off label)","pmid":"38976257","doi":"10.1001/jamainternmed.2024.2525","registryId":null,"population":"41,222 US adults with overweight or obesity on semaglutide (32,029) or tirzepatide (9,193); 18,386 after propensity-score matching; 52.0% of the matched group had type 2 diabetes","comparator":"Semaglutide vs tirzepatide, as prescribed","endpoint":"On-treatment weight change at 3, 6 and 12 months","followUp":"Up to 12 months, on-treatment","result":"Tirzepatide users were more likely to reach 5%, 10% and 15% weight loss (hazard ratios 1.76, 2.54, 3.24)","uncertainty":"Hazard-ratio 95% CIs 1.68-1.84, 2.37-2.73, 2.91-3.61. Weight differences favoring tirzepatide: -2.4% (95% CI -2.5 to -2.2) at 3 months, -4.3% (-4.7 to -4.0) at 6 months, -6.9% (-7.9 to -5.8) at 12 months","discontinuation":"On-treatment analysis: follow-up ended at discontinuation for 55.9% (tirzepatide) and 52.5% (semaglutide), so results describe people while taking the drug and are not comparable to the intention-to-treat results above.","funder":"Not identified: the full text names no funder and has no funding statement (author affiliations are not treated as the funder).","registryResultsPosted":null,"registryMasking":null,"estimand":"Observational cohort, so there is no randomized treatment-regimen or efficacy estimand. The Methods name on-treatment weight loss as the primary estimand of interest: follow-up was censored at the first of treatment discontinuation (30 or more days without medication on hand), switching to a different GLP-1 receptor agonist, last encounter, or study end (3 Nov 2023), and unobserved weights were assumed missing at random. The displayed numbers are this primary on-treatment analysis, so they describe patients while they were taking the drug (follow-up ended at discontinuation for 55.9% of the tirzepatide and 52.5% of the semaglutide group). A separate modified intention-to-treat sensitivity analysis ignored censoring for discontinuation and switching; the supplement reports smaller weight reductions and somewhat attenuated treatment effects, the Discussion describes the differences between the drugs as similar, and it is not the source of any number shown here. Matching cannot remove unmeasured confounding, which the authors acknowledge.","analysisPlan":null,"limitations":["Observational and not randomized: matched groups can still differ in ways that were not measured.","On-treatment analysis, so results describe people while they were taking the drug.","Formulations labeled for type 2 diabetes were used on or off label, and 52.0% of the matched group had type 2 diabetes."],"citation":"Rodriguez and colleagues, JAMA Internal Medicine 2024: cohort study, not a randomized trial. Tirzepatide vs semaglutide (formulations labeled for type 2 diabetes, on or off label). Primary source: https://doi.org/10.1001/jamainternmed.2024.2525 (PMID 38976257). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.4.0, result jama-intern-med-2024-realworld. Versioned record: https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=jama-intern-med-2024-realworld | Result link: https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#jama-intern-med-2024-realworld","releaseVersion":"1.4.0","designLabel":"Observational cohort (not randomized)","designExplanation":"Patients were not randomized. People who chose or were prescribed each drug were matched statistically, so differences can reflect factors that were not measured. Results describe time on treatment only.","verification":{"verifiedOn":"2026-11-14","locators":[{"claim":"Population: 41,222 adults (32,029 semaglutide; 9,193 tirzepatide); 18,386 after matching; 9,563 (52.0%) with type 2 diabetes","source":"Open-access full text","role":"primary","locator":"Results, first paragraph under patient characteristics, and Figure 1 (study flow diagram); matched-cohort characteristics are in the Table.","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/","status":"matched","method":"scripted","checkId":"pmc-jama-population","note":"Read in the PubMed Central copy, which Europe PMC lists as open access (CC BY-NC-ND)."},{"claim":"Hazard ratios 1.76, 2.54 and 3.24 for reaching 5%, 10% and 15% weight loss, with confidence intervals (exact values)","source":"Open-access full text","role":"primary","locator":"Results paragraph on weight-loss thresholds, and the Abstract: the hazard ratios and their 95% confidence intervals are printed in the text.","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/","status":"matched","method":"scripted","checkId":"pmc-jama-hazard-ratios","note":"The article body points to Figure 3 after the hazard-ratio sentence, but the Figure 3 caption describes mean changes within each treatment group and Figure 2 shows event probabilities; the Figure 4 caption and image show the hazard ratios, so WPF follows the figure itself."},{"claim":"Hazard ratios, as plotted for the overall matched cohort","source":"Open-access full text","role":"primary","locator":"Figure 4, panels A to C. Panel A plots the hazard of 5% or greater weight loss, panel B 10% or greater and panel C 15% or greater, each as tirzepatide vs semaglutide. In every panel the category labelled All is the overall matched cohort, shown beside the T2D and No T2D categories.","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/#ioi240039f4","status":"matched","method":"document_read","note":"Read from the figure image in the PubMed Central open-data copy (file md5 matches the bucket manifest). The figure prints no values, so the All points were read by eye as consistent with 1.76, 2.54 and 3.24; exact values come from the text.","quotedSourceText":["All","T2D","No T2D"]},{"claim":"Adjusted weight differences -2.4%, -4.3% and -6.9% at 3, 6 and 12 months, with confidence intervals (exact values)","source":"Open-access full text","role":"primary","locator":"Results paragraph on on-treatment weight change after adjusting for residual confounding, and the Abstract: the differences and their 95% confidence intervals are printed in the text.","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/","status":"matched","method":"scripted","checkId":"pmc-jama-differences","note":"The article body cites Figure 3 after this sentence; Figure 3 shows mean changes within each treatment group, not differences. The differences are plotted in Figure 4."},{"claim":"Adjusted differences, as plotted for the overall matched cohort","source":"Open-access full text","role":"primary","locator":"Figure 4, panels D to F. Panel D plots the difference in percentage change in body weight at 3 months, panel E at 6 months and panel F at 12 months, tirzepatide vs semaglutide among matched patients still on treatment. In every panel the category labelled All is the overall matched cohort, beside the T2D and No T2D categories.","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/#ioi240039f4","status":"matched","method":"document_read","note":"Read from the same figure image. The figure prints no values, so the All points were read by eye as consistent with -2.4, -4.3 and -6.9; exact values come from the text.","quotedSourceText":["All","T2D","No T2D"]},{"claim":"Follow-up ended by discontinuation for 55.9% (tirzepatide) and 52.5% (semaglutide)","source":"Open-access full text","role":"primary","locator":"Results, patient characteristics paragraph (5,140 and 4,823 patients).","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/","status":"matched","method":"scripted","checkId":"pmc-jama-discontinuation"},{"claim":"Estimand and censoring","source":"Open-access full text","role":"primary","locator":"Methods, weight outcomes paragraph: names on-treatment weight loss as the primary estimand of interest, with follow-up censored at the first of treatment discontinuation (30 or more days without medication on hand), switching to a different GLP-1 receptor agonist, last encounter, or study end (3 Nov 2023). Methods, sensitivity analyses: a modified intention-to-treat analysis ignored censoring for discontinuation and switching and used all available follow-up weights.","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/","status":"matched","method":"scripted","checkId":"pmc-jama-estimand","note":"The displayed numbers come from the primary on-treatment analysis. The modified intention-to-treat result is in the paper's supplement figures, which WPF did not read; the authors' Discussion says it showed smaller weight reductions with similar differences between the drugs."},{"claim":"The modified intention-to-treat sensitivity analysis","source":"Open-access full text","role":"primary","locator":"Supplement 2, sections 2.1.1 and 2.1.2 on sensitivity analyses (eFigures 3 to 6): in the modified intention-to-treat analysis, where only administrative censoring applied, fewer patients reached the 5%, 10% and 15% weight-loss thresholds, weight reductions were smaller at every time point, and treatment effects were described as somewhat attenuated.","url":"https://pmc-oa-opendata.s3.amazonaws.com/PMC11231910.1/jamainternmed-e242525-s002.pdf","status":"matched","method":"document_read","note":"Supplement text was read; the plotted eFigure values were not extracted. The Discussion of the paper separately describes the differences between the two drugs as similar under this analysis; the supplement wording is somewhat attenuated, and both are recorded."},{"claim":"The authors' own limitations and disclosures","source":"Open-access full text","role":"primary","locator":"Discussion, Strengths and Limitations paragraph; end matter, Conflict of Interest Disclosures and Author Contributions.","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11231910/","status":"matched","method":"scripted","checkId":"pmc-jama-author-statements","note":"See the authors' statements below. No funding or role-of-funder statement was found."},{"claim":"Publisher article page","source":"Publisher page","role":"primary","locator":"JAMA Network article page for this paper (the PubMed Central copy above was read instead).","url":"https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2821080","status":"not_read","method":"document_read","note":"An automated request to this address returned HTTP 403 on 2026-11-12, which shows the request was blocked. WPF read the open-access PubMed Central copy instead and did not compare it line by line with the publisher page."}],"unverified":["Exact plotted values in Figure 4 and in the supplement's eFigures: the figures print no values (Figure 4) or were not extracted (eFigures), so only the text values are verified numbers.","Funder: the full text names no funder and contains no funding or role-of-funder statement, so it is left unidentified. Author affiliations are not treated as the funder."],"automatedChecks":[{"id":"pmc-jama-population","what":"The full text reports the displayed cohort sizes and the 52.0% type 2 diabetes share.","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the Europe PMC full-text XML, strips markup and matches fragments.","outcome":"Passed on 2026-11-14","lastRun":"2026-11-14"},{"id":"pmc-jama-hazard-ratios","what":"The full text reports the three hazard ratios and their confidence limits.","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the Europe PMC full-text XML and matches fragments.","outcome":"Passed on 2026-11-14","lastRun":"2026-11-14"},{"id":"pmc-jama-differences","what":"The full text reports the three adjusted differences and the 12-month interval.","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the Europe PMC full-text XML and matches fragments.","outcome":"Passed on 2026-11-14","lastRun":"2026-11-14"},{"id":"pmc-jama-discontinuation","what":"The full text reports the two discontinuation shares and counts.","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the Europe PMC full-text XML and matches fragments.","outcome":"Passed on 2026-11-14","lastRun":"2026-11-14"},{"id":"pmc-jama-figure-captions","what":"The captions of Figures 2, 3 and 4 say what the page states they show, including that Figure 4 panels A to C hold hazard ratios and panels D to F hold absolute differences.","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the Europe PMC full-text XML and matches caption fragments.","outcome":"Passed on 2026-11-14","lastRun":"2026-11-14"},{"id":"figure4-image-read","what":"In the Figure 4 image, panels A to C are titled as hazard of weight loss at 5%, 10% and 15% or greater, panels D to F as the difference at 3, 6 and 12 months, and each panel has categories All, T2D and No T2D.","method":"WPF read the downloaded image visually (not scripted, no text extraction). The file's md5 matches the PubMed Central open-data manifest.","outcome":"Read on 2026-11-12; matches the caption","lastRun":"2026-11-12"},{"id":"pmc-jama-estimand","what":"The Methods name on-treatment weight loss as the primary estimand, list the censoring events, and describe the modified intention-to-treat sensitivity analysis.","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the Europe PMC full-text XML and matches fragments.","outcome":"Passed on 2026-11-14","lastRun":"2026-11-14"},{"id":"pmc-jama-author-statements","what":"The limitations and disclosure statements summarized below are present in the full text, and no funding or role-of-funder heading exists in it.","method":"Re-runnable script (scripts/verification/verify-weight-management-sources.mts): fetches the Europe PMC full-text XML, matches fragments and asserts the absence of funding headings.","outcome":"Passed on 2026-11-14","lastRun":"2026-11-14"}],"humanReview":"none recorded","authorStatements":{"source":"Open-access full text (PubMed Central copy), Discussion and end matter, read on 2026-11-12. Paraphrased by WPF.","limitations":["Informative censoring is possible, because patients can see their own weight loss and those seeing none may be more likely to stop or switch drugs. In the modified intention-to-treat analysis the authors' Discussion describes similar differences between the two drugs, while the supplement describes smaller weight reductions and somewhat attenuated treatment effects.","Unmeasured confounding may exist, especially the degree of motivation for weight loss; the authors say a substantial amount would be needed to negate the estimates.","Electronic health record data: adverse events are likely underreported, and weights are recorded only at visits, so event times are likely delayed (the authors expect this to affect both groups similarly).","The imputation model assumed missingness depended only on observed information, which may bias results if unmeasured variables contributed.","Brand was used as a proxy for target dose, so patients may have received doses above or below standard doses.","Health system and payer information were unavailable; the sample covered 35 states but is not representative of the US, which limits generalizability.","Only medications labeled for type 2 diabetes were included."],"disclosures":["One author reported consulting fees from Premier outside the submitted work; no other disclosures were reported."],"funding":"Not identified. The full text has no funding or role-of-funder statement; the author contributions list who obtained funding but do not name a funder. Affiliations are not treated as the funder."}},"versionedRecordUrl":"https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.4.0&resultId=jama-intern-med-2024-realworld","analysisPlanUrl":null,"analysisPlanSections":null,"registryCheckedOn":null,"detailUrl":"https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#jama-intern-med-2024-realworld"}}